FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:969-970 September 28, 2000 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Vascular complications cause serious morbidity in patients with diabetes mellitus. Two such complications are diabetic nephropathy and restenosis after percutaneous transluminal coronary angioplasty. There is currently scant evidence of a genetic marker that predicts which patients will have these complications.

Oxidative stress plays an important part in the development of diabetic vascular complications.¹ Haptoglobin is a hemoglobin-binding protein that has a major role in providing protection against heme-driven oxidative stress.² There are two common alleles for haptoglobin (1 and 2), and the three phenotypes, haptoglobin 1/1, haptoglobin 2/1, and haptoglobin 2/2, differ in their ability to function . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Costacou, T., Ferrell, R. E., Orchard, T. J. (2008). Haptoglobin Genotype: A Determinant of Cardiovascular Complication Risk in Type 1 Diabetes. Diabetes 57: 1702-1706 [Abstract] [Full Text]  
• Asleh, R., Miller-Lotan, R., Aviram, M., Hayek, T., Yulish, M., Levy, J. E., Miller, B., Blum, S., Milman, U., Shapira, C., Levy, A. P. (2006). Haptoglobin Genotype Is a Regulator of Reverse Cholesterol Transport in Diabetes In Vitro and In Vivo. Circ. Res. 99: 1419-1425 [Abstract] [Full Text]  
• Moreno, P. R., Purushothaman, K-R., Sirol, M., Levy, A. P., Fuster, V. (2006). Neovascularization in Human Atherosclerosis. Circulation 113: 2245-2252 [Full Text]  
• Nakhoul, F., Abassi, Z., Morgan, M., Sussan, S., Mirsky, N. (2006). Inhibition of Diabetic Nephropathy in Rats by an Oral Antidiabetic Material Extracted from Yeast. J. Am. Soc. Nephrol. 17: S127-S131 [Abstract] [Full Text]  
• Suleiman, M., Aronson, D., Asleh, R., Kapeliovich, M. R., Roguin, A., Meisel, S. R., Shochat, M., Sulieman, A., Reisner, S. A., Markiewicz, W., Hammerman, H., Lotan, R., Levy, N. S., Levy, A. P. (2005). Haptoglobin Polymorphism Predicts 30-Day Mortality and Heart Failure in Patients With Diabetes and Acute Myocardial Infarction. Diabetes 54: 2802-2806 [Abstract] [Full Text]  
• Asleh, R., Guetta, J., Kalet-Litman, S., Miller-Lotan, R., Levy, A. P. (2005). Haptoglobin Genotype- and Diabetes-Dependent Differences in Iron-Mediated Oxidative Stress In Vitro and In Vivo. Circ. Res. 96: 435-441 [Abstract] [Full Text]  
• Levy, N. S., Levy, A. P. (2004). ELISA for Determination of the Haptoglobin Phenotype. Clin. Chem. 50: 2148-2150 [Full Text]  
• Wang, X., Tanus-Santos, J. E., Reiter, C. D., Dejam, A., Shiva, S., Smith, R. D., Hogg, N., Gladwin, M. T. (2004). Biological activity of nitric oxide in the plasmatic compartment. Proc. Natl. Acad. Sci. USA 101: 11477-11482 [Abstract] [Full Text]  
• Koch, W., Latz, W., Eichinger, M., Gschwendner, C., Teige, B., Schomig, A., Kastrati, A. (2003). Haptoglobin Gene Subtyping by Restriction Enzyme Analysis. Clin. Chem. 49: 1937-1940 [Full Text]  
• Levy, A. P., Hochberg, I., Jablonski, K., Resnick, H. E., Lee, E. T., Best, L., Howard, B. V. (2002). Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the strong heart study. J Am Coll Cardiol 40: 1984-1990 [Abstract] [Full Text]  
• Koch, W., Latz, W., Eichinger, M., Roguin, A., Levy, A. P., Schomig, A., Kastrati, A. (2002). Genotyping of the Common Haptoglobin Hp 1/2 Polymorphism Based on PCR. Clin. Chem. 48: 1377-1382 [Abstract] [Full Text]  
• Zarins, C. K. (2001). Discussion. VASC ENDOVASCULAR SURG 35: 351-351